The G2Solutions project, led by Prof. Dr. Ir. Floris Foijer from the UMCG – ERIBA Research Institute, has received funding from PharmaNL under the PharmaNL Shared Development Infrastructure program for their five-year project. G2Solutions focuses on developing infrastructure for new drug development. “This project demonstrates that we can make unique technologies, such as single-cell sequencing and stem cell and organoid production, available to the world, creating new opportunities for drug development,” says Peter Ketelaar, director of LIFE Cooperative. The project involves close collaboration between UMCG/ERIBA, UMCG/Genetics, LIFE Cooperative, GenomeScan, and Pivot Park Screening Centre.
G2Solutions utilizes groundbreaking technologies, including single-cell genomics. This technology, in which UMCG is a global leader, allows for the analysis of the genome of individual cells. This is crucial for chronic and complex diseases such as cancer, where the genome of cancer cells often shows significant variations. Instead of obtaining an average picture from millions of cells in a tissue, single-cell sequencing provides insights into the genetic abnormalities of individual cells. “The unique aspect of our approach is that we can read the DNA of individual cells, allowing us to examine much more closely what is happening within a tumor,” explains Foijer.
The techniques being developed in the project not only have scientific value but also significant commercial applications. Floris Foijer emphasizes that one of the main goals is to explore whether these technologies can be made widely accessible and affordable for diagnostics and therapies. Peter Ketelaar adds: “The biggest challenge for the business side is to find the right product-market combinations that can lead to sustainable success. We need to make technologies that are currently working in the lab affordable and applicable for a broader and international market.”
The project aims to make this infrastructure available to other pharmaceutical and academic partners, both nationally and internationally. Pivot Park Screening Centre, GenomeScan, and LIFE Cooperative are involved in further developing and marketing these technologies. Brigitte Drees from Pivot Park Screening Centre: “In this project, we are using our expertise to accelerate and optimize the development of new technologies. With our extensive experience in high-content screening and bioprofiling services, we contribute to identifying promising leads for drug development, which is crucial for the success of this innovative project.”
Kees van den Berg, CEO of GenomeScan explains: “At GenomeScan, we have extensive knowledge and experience in developing existing sequencing technologies from academia into a commercial facility for pharmaceutical and biotech companies. We will also apply this expertise to this innovative project.”
Ultimately, the goal is to establish a commercial company that will continuously offer the acquired knowledge and improved techniques. Foijer: “It’s an exciting journey to see whether we can bring academic technology to the market within five years. This project brings together science, technology, and entrepreneurship – a unique opportunity to achieve groundbreaking innovations.”
Floris Foijer and Peter Ketelaar also share some tips for future grant applicants at PharmaNL. Peter emphasizes that a successful grant application requires both strong technology and experienced entrepreneurs with market knowledge. “The core technology must be solid and fairly unique,” he says. “Additionally, you need to involve people who know how to bring new products and technologies to market. Understand the landscape of the subsidy world and the requirements, such as those of the funding provider.”
Floris adds that intrinsic motivation for collaboration and openness is crucial. “You need to have the desire to make your resources available, not just to secure funding for your own organization,” he explains. “Creating truly open infrastructure requires a willingness to share and collaborate.”
The development of this project has been made possible with the support of the Municipality of Groningen and the Municipality of Assen, the Province of Groningen, Drenthe, and Fryslân.
Source text: PharmaNL
Photo: Mathilde Broekhuis and Laura Kempe (two professionals at ERIBA) at the robot, photographer Floris Foijer.
In the North, and in Groningen in particular, there are dozens of companies working on innovations in the fields of life sciences and health. There are many hidden gems among them, says Ronald Hesse, director of the LIFE Cooperative partnership. “Millions of patients worldwide have already benefited from innovations developed here in Groningen,” he says.
Researchers at the UMCG and their spin-off CC Diagnostics, located on Campus Groningen, have developed a new test that could make cervical cancer screening more efficient and user-friendly.
A full house, sharp discussions, and an afternoon in which science and industry visibly strengthened one another. The Dutch Medicines Winter Afternoon demonstrated that Groningen is not only a strong geographical spot, but also a substantive force within the Dutch life sciences landscape. The event, organized by FIGON (Federation for Innovative Drug Research Netherlands) in collaboration with LIFE Cooperative, brought professionals from across the Netherlands to the north. Researchers, entrepreneurs, developers, and clinical experts gathered around one shared ambition: to bring innovative medicines to patients faster, smarter, and better.Klaas Poelstra, Chair of FIGON, looks back positively on the event: “It was great to see local businesses in the health sector and leading academic scientists engaging in conversation with one another. They have so much to gain from each other.“From what to how What became particularly clear during the Dutch Medicines Winter Afternoon was how rapidly the field of drug development is evolving, and how essential collaboration has become. At a time when therapies are increasingly targeted, complex, and costly, the focus is shifting from only what we develop to how we do so: more intelligently, more sustainably, and better aligned with patient needs. This broader context was already reflected in the opening remarks by Klaas Poelstra, who emphasized the importance of continued innovation for the Netherlands’ competitive position and patient care. On behalf of the LIFE Cooperative, Robert Hof highlighted that regional collaboration is a decisive factor: by bringing science, entrepreneurship, and clinical practice closer together, real acceleration can be achieved. The first substantive contributions made it clear that innovation today is not only about new molecules, but also about new delivery methods. Rob Steendam demonstrated how long-acting microspheres can improve treatment adherence and reduce patient burden. Jaap Wieling showed how inhalation technology is evolving into a platform for both local and systemic therapies. Through her research on polyelectrolyte coacervates, Marleen Kamperman placed these innovations within a fundamental scientific framework. After the break, the discussion shifted to clinical translation and advanced nanomedicines. Flávia Sousa illustrated how polymer-based nanomedicines contribute to targeted brain delivery. Ad Roffel underscored the importance of robust pharmacokinetic studies in an era where the demands for evidence continue to increase. Erik Frijlink reflected on innovation within both existing and new delivery systems, while Helder Santos outlined the potential of RNA delivery via nanotechnology for cardiac tissue repair.More than a program During the closing networking reception, it became clear what participants had gained from the afternoon. As Robert Hof, Board Member of the LIFE Cooperative, put it: “The FIGON Winter Afternoon was an excellent event with distinguished speakers and strong engagement. We look forward to the next edition and extend our sincere thanks to Klaas Poelstra and FIGON for hosting the event in the Northern Netherlands.” The common thread throughout the afternoon was therefore unmistakable: the future of medicines does not lie within a single discipline, but in the connections between them. In a time of increasing healthcare pressure, rapid technological advancement, and international competition, such collaboration is not a luxury—it is a necessity. The Dutch Medicines Winter Afternoon showed that this collaboration is firmly rooted in the Northern Netherlands and that Groningen is positioning itself emphatically as a breeding ground and accelerator for innovative drug development.
